Q2 2018 EPS Estimates for Insulet Corporation Increased by Northcoast Research (PODD)
Insulet Corporation (NASDAQ:PODD) – Analysts at Northcoast Research boosted their Q2 2018 earnings estimates for Insulet Corporation in a research note issued to investors on Friday. Northcoast Research analyst E. Snyder now forecasts that the medical instruments supplier will post earnings of $0.00 per share for the quarter, up from their previous estimate of ($0.01).
Several other brokerages also recently issued reports on PODD. Oppenheimer Holdings, Inc. set a $46.00 price objective on shares of Insulet Corporation and gave the stock a “hold” rating in a research note on Tuesday, May 9th. William Blair reissued an “outperform” rating on shares of Insulet Corporation in a report on Thursday, May 25th. ValuEngine raised shares of Insulet Corporation from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Jefferies Group LLC reissued a “buy” rating and set a $48.00 price objective on shares of Insulet Corporation in a report on Friday, July 14th. Finally, Zacks Investment Research lowered shares of Insulet Corporation from a “buy” rating to a “hold” rating in a report on Thursday, July 20th. Eight analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Insulet Corporation currently has an average rating of “Buy” and an average target price of $49.69.
WARNING: “Q2 2018 EPS Estimates for Insulet Corporation Increased by Northcoast Research (PODD)” was first published by Daily Political and is the property of of Daily Political. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/08/08/q2-2018-eps-estimates-for-insulet-corporation-increased-by-northcoast-research-podd.html.
Insulet Corporation (NASDAQ:PODD) traded up 1.54% on Monday, reaching $54.71. The company’s stock had a trading volume of 75,254 shares. Insulet Corporation has a one year low of $30.69 and a one year high of $54.85. The company’s market capitalization is $3.17 billion. The firm has a 50-day moving average of $50.00 and a 200-day moving average of $44.62.
Insulet Corporation (NASDAQ:PODD) last released its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported ($0.13) EPS for the quarter, meeting analysts’ consensus estimates of ($0.13). The business had revenue of $110 million during the quarter, compared to analyst estimates of $106.23 million. Insulet Corporation had a negative return on equity of 46.88% and a negative net margin of 7.30%. Insulet Corporation’s quarterly revenue was up 26.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.08) EPS.
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Prudential Financial Inc. increased its stake in shares of Insulet Corporation by 42.0% in the second quarter. Prudential Financial Inc. now owns 8,282 shares of the medical instruments supplier’s stock valued at $425,000 after buying an additional 2,450 shares during the last quarter. Geneva Advisors LLC boosted its stake in shares of Insulet Corporation by 2.3% in the second quarter. Geneva Advisors LLC now owns 22,215 shares of the medical instruments supplier’s stock valued at $1,140,000 after buying an additional 504 shares during the period. Marshall Wace North America L.P. bought a new stake in shares of Insulet Corporation during the second quarter valued at approximately $8,882,000. Turner Investments LLC bought a new stake in shares of Insulet Corporation during the second quarter valued at approximately $334,000. Finally, Frontier Capital Management Co. LLC boosted its stake in shares of Insulet Corporation by 2.8% in the second quarter. Frontier Capital Management Co. LLC now owns 1,809,473 shares of the medical instruments supplier’s stock valued at $92,844,000 after buying an additional 50,019 shares during the period.
In other Insulet Corporation news, EVP Bradley A. Thomas acquired 3,000 shares of the stock in a transaction on Thursday, May 11th. The shares were bought at an average cost of $38.69 per share, with a total value of $116,070.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Michael P. Spears acquired 2,500 shares of the stock in a transaction on Tuesday, May 16th. The shares were acquired at an average cost of $40.59 per share, for a total transaction of $101,475.00. The disclosure for this purchase can be found here. Insiders bought a total of 8,080 shares of company stock worth $317,339 over the last 90 days. Company insiders own 2.60% of the company’s stock.
About Insulet Corporation
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).
Receive News & Ratings for Insulet Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet Corporation and related companies with MarketBeat.com's FREE daily email newsletter.